Dean Investment Associates LLC Decreases Stock Holdings in Addus HomeCare Co. (NASDAQ:ADUS)

Dean Investment Associates LLC cut its stake in Addus HomeCare Co. (NASDAQ:ADUS) by 80.0% in the third quarter, Holdings Channel reports. The fund owned 4,922 shares of the company’s stock after selling 19,721 shares during the period. Dean Investment Associates LLC’s holdings in Addus HomeCare were worth $655,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. UMB Bank n.a. boosted its holdings in Addus HomeCare by 64.2% during the 2nd quarter. UMB Bank n.a. now owns 225 shares of the company’s stock valued at $26,000 after acquiring an additional 88 shares during the period. Quarry LP acquired a new stake in shares of Addus HomeCare during the 3rd quarter worth about $28,000. Quest Partners LLC acquired a new position in Addus HomeCare during the second quarter worth approximately $31,000. Innealta Capital LLC acquired a new position in Addus HomeCare during the second quarter worth approximately $44,000. Finally, Farther Finance Advisors LLC increased its holdings in shares of Addus HomeCare by 9,150.0% in the third quarter. Farther Finance Advisors LLC now owns 370 shares of the company’s stock valued at $49,000 after purchasing an additional 366 shares during the period. 95.35% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Addus HomeCare

In other Addus HomeCare news, CEO R Dirk Allison sold 12,500 shares of the firm’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $123.16, for a total transaction of $1,539,500.00. Following the completion of the sale, the chief executive officer now owns 141,897 shares in the company, valued at $17,476,034.52. This trade represents a 8.10 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Esteban Lopez sold 500 shares of the firm’s stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $127.50, for a total value of $63,750.00. Following the sale, the director now owns 3,366 shares of the company’s stock, valued at approximately $429,165. This trade represents a 12.93 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 4.60% of the company’s stock.

Addus HomeCare Price Performance

Addus HomeCare stock opened at $120.74 on Monday. The stock’s 50-day moving average is $126.26 and its 200-day moving average is $124.16. The company has a market cap of $2.19 billion, a price-to-earnings ratio of 27.63, a price-to-earnings-growth ratio of 2.16 and a beta of 1.01. Addus HomeCare Co. has a 12 month low of $85.94 and a 12 month high of $136.12.

Addus HomeCare (NASDAQ:ADUS) last announced its earnings results on Monday, November 4th. The company reported $1.30 EPS for the quarter, beating the consensus estimate of $1.28 by $0.02. The business had revenue of $289.80 million for the quarter, compared to the consensus estimate of $289.42 million. Addus HomeCare had a return on equity of 9.62% and a net margin of 6.50%. The company’s revenue was up 7.1% on a year-over-year basis. During the same period last year, the business posted $1.03 EPS. Research analysts anticipate that Addus HomeCare Co. will post 4.59 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the company. KeyCorp assumed coverage on Addus HomeCare in a research note on Friday, October 11th. They issued an “overweight” rating and a $150.00 price target on the stock. Macquarie reaffirmed an “outperform” rating and set a $139.00 price objective on shares of Addus HomeCare in a research note on Monday, November 4th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $136.00 price objective on shares of Addus HomeCare in a research note on Thursday, November 14th. Oppenheimer increased their target price on Addus HomeCare from $140.00 to $145.00 and gave the stock an “outperform” rating in a research report on Monday, September 23rd. Finally, StockNews.com downgraded Addus HomeCare from a “buy” rating to a “hold” rating in a research report on Tuesday, December 3rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Addus HomeCare presently has a consensus rating of “Moderate Buy” and a consensus target price of $131.63.

About Addus HomeCare

Addus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States. The company operates through three segments: Personal Care, Hospice, and Home Health.